A team headed by Claude Perreault, Director of IRIC's Immunobiology Research Unit and Professor at the Faculty of Medicine at Université de Montréal, has identified novel tumor antigens that could ...

A new platform developed by researchers at the University of Texas MD Anderson Cancer Center quickly finds and isolates rare, ...

Amid an evolving landscape of anticancer agents, numerous approaches to elicit tumor-specific immune responses are under active investigation. In broad terms, these approaches have traditionally ...

Therapeutic cancer vaccines have experienced a remarkable resurgence over the past decade, representing a paradigm shift in oncology toward harnessing the immune system's intrinsic ability to combat ...

Scientists from the Moffitt Cancer Center say they now have a better understanding why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings ...

A research team has introduced a novel cancer immunotherapy strategy. This approach involves attaching "fake targets" to tumor cells to guide immune cell attacks, overcoming the limitations of ...

Professor Zhaohui Tang and Associate Professor Zhilin Liu from the team of Professor Xuesi Chen at the Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, developed ...

• This study aimed to investigate the immunophenotype of esophageal cancer (ESCA) by assessing the patient’s immune defenses or autoimmune function and to identify potential tumor antigens and ...

A team of researchers has found new insight into why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings may help improve future ways to deliver ...

A second prostate-specific membrane antigen (PSMA) PET scan changed treatment plans for nearly half of patients whose first ...